galantamine hydrobromide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 47 Diseases   10 Trials   10 Trials   1303 News 


«12...45678910111213141516»
  • ||||||||||  galantamine hydrobromide / generics, rivastigmine / generics
    Review, Journal:  Experimental evidence for use of Acorus calamus (asarone) for cancer chemoprevention. (Pubmed Central) -  Jun 14, 2019   
    Still, extensive in-vivo studies are necessary using various animal models to understand the molecular mechanism behind the pharmacological activity of the bioactive phytochemicals derived from A. calamus. It is strongly believed that the comprehensive evidence presented in this article could deliver a possible source for researchers to conduct future studies pertaining to A. calamus and/or its bioactive phytochemicals asarone for cancer chemoprevention.
  • ||||||||||  Review, Journal:  Pharmacological Management of Dementia with Lewy Bodies. (Pubmed Central) -  Jun 6, 2019   
    Two agents targeting alpha-synuclein (NPT200-11 and ambroxol) currently hold promise as disease-modifying therapies for DLB, but they are yet to be tested in clinical trials. An agent (E2027) that offers hope of neuroprotection by increasing central cyclic guanosine monophosphate (cGMP) levels is currently being examined in clinical trials in DLB patients.
  • ||||||||||  donepezil / generics, galantamine hydrobromide / generics
    Journal:  Is it personalized treatment of dementia based on the CYP2D6 gene polymorphism possible? (Pubmed Central) -  Jun 4, 2019   
    Therefore, the early treatment with the combination of CI and memantine may be effective in treatment of DLB. There was no association between the CYP2D6 genotype and the efficacy of antidementia therapy (OR=0,44, 95% CI -3.0-1,38; p=0,46).
  • ||||||||||  galantamine hydrobromide / generics
    Preclinical, Journal:  Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice. (Pubmed Central) -  Apr 9, 2019   
    Our findings indicated that Schisanhenol can attenuate scopolamine-induced learning impairment and enhance cognitive function, the mechanism via improve the cholinergic system and antioxidant ability, activate SIRT1-PGC1α signaling, inhibit the phosphorylation of Tau, and would be an effective candidate against cognitive disorders, such as Alzheimer's disease. These findings indicate that galantamine could be a promising treatment to improve endotoxin-induced cognitive decline and neuroinflammation in neurodegenerative diseases.
  • ||||||||||  galantamine hydrobromide / generics
    Journal:  Multifunctional approaches to provide potential pharmacophores for the pharmacy shelf: Heracleum sphondylium L. subsp. ternatum (Velen.) Brummitt. (Pubmed Central) -  Apr 9, 2019   
    The extracts exhibited low inhibition against amylase (0.12-0.84 mmol acarbose equivalent (ACAE)/g extract) and a more pronounced inhibition against glucosidase (2.29-3.65 mmol ACAE/g extract)...The methanol extract (0.78 mg/ml) showed moderate antifungal activity while the ethyl acetate extract (0.78-3.12 mg/ml) showed weak to moderate antimicrobial activity. This study provides valuable baseline data which might serve for the development of future pharmacophores for the management of human ailments.
  • ||||||||||  galantamine hydrobromide / generics
    PK/PD data, Preclinical, Journal:  Nose to brain delivery of galantamine loaded nanoparticles: In-vivo pharmacodynamic and biochemical study in mice. (Pubmed Central) -  Apr 7, 2019   
    This study provides valuable baseline data which might serve for the development of future pharmacophores for the management of human ailments. Significant recovery in amnesia induced mice model by intranasal administration of galantamine loaded thiolated chitosan nanoparticles established the relevance of nose to brain delivery over the conventional oral therapies for the treatment of Alzheimer's disease.
  • ||||||||||  donepezil / generics, galantamine hydrobromide / generics, rivastigmine / generics
    Retrospective data, Journal:  Comparison of prescribing practices for older adults treated by female versus male physicians: A retrospective cohort study. (Pubmed Central) -  Apr 7, 2019   
    There is a statistically significant and important difference in ChEI prescribing patterns between female and male physicians, suggesting that female physicians may be more careful and conservative in their approaches. This will inform future research to determine if patients receiving lower-than-recommended initial doses also have better outcomes.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    Targeting Nicotinic and NMDA Receptors Concurrently: Rocket Science, Common Sense or Game Changer? (Regency S-V) -  Apr 3, 2019 - Abstract #SIRS2019SIRS_140;    
    Hence, this combination could be the first antischizophrenia treatment, improving positive, cognitive, and negative symptoms concurrently with KYNA, mismatch negativity, brain-derived neurotrophic factor, prepulse inhibition, gamma oscillation, and oxidative stress/antioxidant as biomarkers. Hence, an RCT with this combination is warranted.
  • ||||||||||  galantamine hydrobromide / generics
    Journal:  Selected essential oils inhibit key physiological enzymes and possess intracellular and extracellular antimelanogenic properties in vitro. (Pubmed Central) -  Apr 3, 2019   
    ...CH and CR were found to significantly inhibit (2.476 ± 0.13 μg/mL and 3.636 ± 0.10 μg/mL, respectively) acetylcholinesterase, compared with galantamine (3.989 ± 0.16 μg/mL)...In addition, CH, CR, CGp, CZ, and PT were found to significantly inhibit α-glucosidase (276.70 ± 0.73 μg/mL, 169.90 ± 0.58 μg/mL, 240.60 ± 6.50 μg/mL, 64.52 ± 0.69 μg/mL, and 313.0 ± 5.0 μg/mL, respectively), compared to acarbose (448.80 ± 0.81 μg/mL)...The EOs also inhibited intracellular (50% inhibitory concentration 15.92 ± 1.06 μg/mL, 23.75 ± 4.47 μg/mL, and 28.99 ± 5.70 μg/mL for CH, CR, and CGp, respectively) and extracellular (< 15.625 μg/mL for CH, CR, CGp, and PT) melanin production when tested against B16F10 mouse melanocytes. Results from the present study tend to show that EOs extracted from these medicinal plants can inhibit key enzymes and may be potential candidates for cosmetic and pharmaceutical industries.
  • ||||||||||  donepezil / generics, galantamine hydrobromide / generics, rivastigmine / generics
    Clinical, Journal:  Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease. (Pubmed Central) -  Mar 29, 2019   
    The present study suggests that despite a relatively lower dose of ChEI after the switch, switching from donepezil or rivastigmine preserved cognitive functions for at least 6 M. Switching from galantamine to rivastigmine improved Mini-Mental State Examination and ABS at 3 M, but did not improve ADL scores. Geriatr Gerontol Int 2017; 17: 1843-1848.
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  RDVCGH: Racial Differences in Vagal Control of Glucose Homeostasis (clinicaltrials.gov) -  Mar 19, 2019   
    P1/2,  N=23, Completed, 
    Geriatr Gerontol Int 2017; 17: 1991-1999. Recruiting --> Completed | Trial completion date: Oct 2018 --> Oct 2017 | Trial primary completion date: Oct 2018 --> Oct 2017
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Trial completion date, Trial primary completion date:  Effects of Galantamine on Cognition (clinicaltrials.gov) -  Mar 4, 2019   
    P2,  N=24, Active, not recruiting, 
    Recruiting --> Completed | Trial completion date: Oct 2018 --> Oct 2017 | Trial primary completion date: Oct 2018 --> Oct 2017 Trial completion date: Oct 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Dec 2019
  • ||||||||||  Kinaction (masitinib) / AB Science
    Enrollment change, Trial completion date, Trial primary completion date:  Masitinib in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) -  Dec 5, 2018   
    P3,  N=721, Active, not recruiting, 
    Trial completion date: Oct 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Dec 2019 N=396 --> 721 | Trial completion date: Dec 2016 --> Oct 2019 | Trial primary completion date: Dec 2015 --> Apr 2019
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Trial primary completion date:  RDVCGH: Racial Differences in Vagal Control of Glucose Homeostasis (clinicaltrials.gov) -  Aug 13, 2018   
    P1/2,  N=24, Recruiting, 
    N=27 --> 43 Trial primary completion date: May 2018 --> Aug 2018
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Trial primary completion date:  RDVCGH: Racial Differences in Vagal Control of Glucose Homeostasis (clinicaltrials.gov) -  Jan 25, 2018   
    P1/2,  N=24, Recruiting, 
    Recruiting --> Completed Trial primary completion date: Oct 2017 --> May 2018
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date, Adverse events:  Pharmacovigilance in Gerontopsychiatric Patients (clinicaltrials.gov) -  Oct 19, 2017   
    P3,  N=407, Terminated, 
    Active, not recruiting --> Recruiting N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017
  • ||||||||||  galantamine hydrobromide / Generic mfg., pyridostigmine Bromide / Generic mfg.
    Enrollment open, Trial initiation date, Trial primary completion date, Reflex:  Vagal Stimulation in POTS (clinicaltrials.gov) -  Sep 14, 2017   
    P1,  N=16, Recruiting, 
    N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017 Not yet recruiting --> Recruiting | Initiation date: Jul 2017 --> Sep 2017 | Trial primary completion date: Jul 2019 --> Jul 2020
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Trial primary completion date:  Effects of Galantamine on Cognition (clinicaltrials.gov) -  Aug 7, 2017   
    P2,  N=24, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Jul 2017 --> Sep 2017 | Trial primary completion date: Jul 2019 --> Jul 2020 Trial primary completion date: Jan 2017 --> Oct 2018
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Enrollment open:  SAHRANG: Subarachnoid Hemorrhage Recovery And Galantamine (clinicaltrials.gov) -  May 5, 2017   
    P1/2,  N=60, Recruiting, 
    Trial primary completion date: Jan 2017 --> Oct 2018 Not yet recruiting --> Recruiting
  • ||||||||||  galantamine hydrobromide / Generic mfg., pyridostigmine Bromide / Generic mfg.
    New P1 trial, Reflex:  Vagal Stimulation in POTS (clinicaltrials.gov) -  Apr 20, 2017   
    P1,  N=16, Not yet recruiting, 
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Trial primary completion date:  RDVCGH: Racial Differences in Vagal Control of Glucose Homeostasis (clinicaltrials.gov) -  Feb 24, 2017   
    P1/2,  N=24, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Oct 2017
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Trial initiation date, Trial primary completion date:  COGICRehab: Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment (clinicaltrials.gov) -  Dec 7, 2016   
    P2,  N=30, Recruiting, 
    Trial primary completion date: Mar 2017 --> Oct 2017 Initiation date: Jul 2011 --> Nov 2011 | Trial primary completion date: Jan 2015 --> Nov 2017
  • ||||||||||  galantamine hydrobromide / Generic mfg.
    Enrollment closed, Trial primary completion date:  Effects of Galantamine on Cognition (clinicaltrials.gov) -  Jun 27, 2016   
    P2,  N=24, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jan 2017
  • ||||||||||  methylphenidate tablet / Generic mfg., galantamine hydrobromide / Generic mfg.
    Trial primary completion date:  STREAM-VCI: Symptomatic Treatment of Vascular Cognitive Impairment (clinicaltrials.gov) -  May 3, 2016   
    P2/3,  N=30, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jan 2017 Trial primary completion date: Feb 2016 --> Dec 2016
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Enrollment change, Trial termination, HEOR:  COMET-AD: Comparative Research of Alzheimer's Disease Drugs (clinicaltrials.gov) -  Apr 14, 2016   
    P=N/A,  N=200, Terminated, 
    Trial primary completion date: Feb 2016 --> Dec 2016 N=300 --> 200 | Active, not recruiting --> Terminated; Low study accrual caused the study to be ended early.